Inhaled iloprost as third add-on therapy in idiopathic pulmonary arterial hypertension

Abstract

Triple combination therapy is suggested in current pulmonary arterial hypertension guidelines in case of unsatisfactory treatment with oral double combination therapy. However, there is a lack of evidence concerning some of the drug combinations currently employed. We demonstrate the clinical and hemodynamical benefits of inhaled iloprost as third add-on therapy in idiopathic pulmonary arterial hypertension.

Read the full article online

Topics

Hemodynamics
Pulmonary Arterial Hypertension

Authors

Caio J.C.S. Fernandes, Taysa A.F. da Silva, Jose L. Alves Jr, Carlos V.P. Jardim, Rogerio de Souza

Published in:

Pulmonary Circulation Vol 11: No 1 cover image

January 2021

Pulmonary Circulation Vol 11: No 1

View this journal

Related articles


Acute effect of inhaled iloprost on exercise dynamic hyperinflation in COPD patients: A randomized crossover study.

Authors: Lammi MR, Ghonim MA, Johnson J, D'Aquin J, Zamjahn JB, Pellett A, Okpechi SC, Romaine C, Pyakurel K, Luu HH, Shellito JE, Boulares AH, deBoisblanc BP Source: Respir Med


Comparison of levosimendan, NO, and inhaled iloprost for pulmonary hypertension reversibility assessment in heart transplant candidates.

Authors: Tavares-Silva M, Saraiva F, Pinto R, Amorim S, Silva JC, Leite-Moreira AF, Maciel MJ, Lourenço AP Source: ESC Heart Fail

Inhaled iloprost as third add-on therapy in idiopathic pulmonary arterial hypertension.

Authors: Fernandes CJCS, da Silva TAF, Alves JL Jr, Jardim CVP, de Souza R Source: Pulm Circ

Acute vasoreactivity testing predicts outcome of idiopathic pulmonary arterial hypertension patients with a negative acute response.

Authors: Sun Y, Li Y, Meng X, Jiang R, Zhao Q, Wang L, Shi L, Luo C, Qiu H, Wu W, Li J, He J, Liu J, Yuan P, Gong S Source: Ann Transl Med

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI
standard-example-image.jpg